Notch2 is a crucial regulator of self-renewal and tumorigenicity in human hepatocellular carcinoma cells

Oncology Reports

Volumn 36, Issue 1, 2016, Pages 181-188

  Wu, Wen Rui ^a   Zhang, Rui ^a   Shi, Xiang De ^a   Yi, Cao ^a   Xu, Lei Bo ^a   Liu, Chao ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Notch2; Self renewal; Tumorigenicity

Indexed keywords

FLUOROURACIL; NOTCH2 RECEPTOR; SMALL INTERFERING RNA; THY 1 ANTIGEN; NOTCH2 PROTEIN, HUMAN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STEM CELL; CARCINOGENESIS; CARCINOGENICITY; CELL CYCLE PROGRESSION; CELL PROLIFERATION ASSAY; CELL SELF-RENEWAL; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; FEMALE; GENE SILENCING; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NOTCH2 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RNA INTERFERENCE; TUMOR GROWTH; TUMOR INVASION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL PROLIFERATION; GENETICS; HEP-G2 CELL LINE; LIVER NEOPLASMS; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; BIOMARKERS, TUMOR; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; RECEPTOR, NOTCH2; RNA INTERFERENCE; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 84971492155     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.4831     Document Type: Article

References (30)

1. Singh S, Singh PP, Roberts LR and Sanchez W: Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 11: 45-54, 2014.
2. Motola-Kuba D, Zamora-Valdés D, Uribe M and Méndez-Sánchez N: Hepatocellular carcinoma. An overview. Ann Hepatol 5: 16-24, 2006.
3. Li Y, Tang ZY and Hou JX: Hepatocellular carcinoma: Insight from animal models. Nat Rev Gastroenterol Hepatol 9: 32-43, 2011.
4. Woo HG, Wang XW, Budhu A, Kim YH, Kwon SM, Tang ZY, Sun Z, Harris CC and Thorgeirsson SS: Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. Gastroenterology 140: 1063-1070, 2011.
5. Oishi N and Wang XW: Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci 7: 517-535, 2011.
6. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A, Ng I, Man K, Wong N, To KF, et al: miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 7: 694-707, 2010.
7. Tong CM, Ma S and Guan XY: Biology of hepatic cancer stem cells. J Gastroenterol Hepatol 26: 1229-1237, 2011.
8. Penton AL, Leonard LD and Spinner NB: Notch signaling in human development and disease. Semin Cell Dev Biol 23: 450-457, 2012.
9. Gray GE, Mann RS, Mitsiadis E, Henrique D, Carcangiu ML, Banks A, Leiman J, Ward D, Ish-Horowitz D and Artavanis-Tsakonas S: Human ligands of the Notch receptor. Am J Pathol 154: 785-794, 1999.
10. Yoneya T, Tahara T, Nagao K, Yamada Y, Yamamoto T, Osawa M, Miyatani S and Nishikawa M: Molecular cloning of delta-4, a new mouse and human Notch ligand. J Biochem 129: 27-34, 2001.
11. Galic V, Shawber CJ, Reeves C, Shah M, Murtomaki A, Wright J, Herzog T, Tong GX and Kitajewski J: NOTCH2 expression is decreased in epithelial ovarian cancer and is related to the tumor histological subtype. Pathol Discov 1: 4, 2013.
12. Sehrawat A, Sakao K and Singh SV: Notch2 activation is protective against anticancer effects of zerumbone in human breast cancer cells. Breast Cancer Res Treat 146: 543-555, 2014.
13. Mazur PK, Einwächter H, Lee M, Sipos B, Nakhai H, Rad R, Zimber-Strobl U, Strobl LJ, Radtke F, Klöppel G, et al: Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA 107: 13438-13443, 2010.
14. Wang WJ, Yao Y, Jiang LL, Hu TH, Ma JQ, Ruan ZP, Tian T, Guo H, Wang SH and Nan KJ: Increased LEF1 expression and decreased Notch2 expression are strong predictors of poor outcomes in colorectal cancer patients. Dis Markers 35: 395-405, 2013.
15. Yu S, Zhang R, Liu F, Wang H, Wu J and Wang Y: Notch inhibition suppresses nasopharyngeal carcinoma by depleting cancer stem-like side population cells. Oncol Rep 28: 561-566, 2012.
16. Sparks EE, Huppert KA, Brown MA, Washington MK and Huppert SS: Notch signaling regulates formation of the three-dimensional architecture of intrahepatic bile ducts in mice. Hepatology 51: 1391-1400, 2010.
17. Geisler F, Nagl F, Mazur PK, Lee M, Zimber-Strobl U, Strobl LJ, Radtke F, Schmid RM and Siveke JT: Liver-specific inactivation of Notch2, but not Notch1, compromises intrahepatic bile duct development in mice. Hepatology 48: 607-616, 2008.
18. Gao J, Song Z, Chen Y, Xia L, Wang J, Fan R, Du R, Zhang F, Hong L, Song J, et al: Deregulated expression of Notch receptors in human hepatocellular carcinoma. Dig Liver Dis 40: 114-121, 2008.
19. Dill MT, Tornillo L, Fritzius T, Terracciano L, Semela D, Bettler B, Heim MH and Tchorz JS: Constitutive Notch2 signaling induces hepatic tumors in mice. Hepatology 57: 1607-1619, 2013.
20. Jeliazkova P, Jörs S, Lee M, Zimber-Strobl U, Ferrer J, Schmid RM, Siveke JT and Geisler F: Canonical Notch2 signaling determines biliary cell fates of embryonic hepatoblasts and adult hepatocytes independent of Hes1. Hepatology 57: 2469-2479, 2013.
21. Kamath BM, Bauer RC, Loomes KM, Chao G, Gerfen J, Hutchinson A, Hardikar W, Hirschfield G, Jara P, Krantz ID, et al: NOTCH2 mutations in Alagille syndrome. J Med Genet 49: 138-144, 2012.
22. McCright B, Lozier J and Gridley T: A mouse model of Alagille syndrome: Notch2 as a genetic modifier of Jag1 haploinsufficiency. Development 129: 1075-1082, 2002.
23. Tchorz JS, Kinter J, Müller M, Tornillo L, Heim MH and Bettler B: Notch2 signaling promotes biliary epithelial cell fate specification and tubulogenesis during bile duct development in mice. Hepatology 50: 871-879, 2009.
24. Yen WC, Fischer MM, Axelrod F, Bond C, Cain J, Cancilla B, Henner WR, Meisner R, Sato A, Shah J, et al: Targeting notch signaling with a notch2/notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin Cancer Res 21: 2084-2095, 2015.
25. Giovannini C, Gramantieri L, Chieco P, Minguzzi M, Lago F, Pianetti S, Ramazzotti E, Marcu KB and Bolondi L: Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. J Hepatol 50: 969-979, 2009.
26. Litten JB, Chen TT, Schultz R, Herman K, Comstock J, Schiffman J, Tomlinson GE and Rakheja D: Activated NOTCH2 is overexpressed in hepatoblastomas: an immunohistochemical study. Pediatr Dev Pathol 14: 378-383, 2011.
27. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA and Dick JE: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648, 1994.
28. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001.
29. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC and Dirks PB: Tumour-initiating cells: Challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8: 806-823, 2009.
30. Sukowati CH, Anfuso B, Torre G, Francalanci P, Crocè LS and Tiribelli C: The expression of CD90/Thy-1 in hepatocellular carcinoma: An in vivo and in vitro study. PLoS One 8: e76830, 2013.